Question special
Resident

First, I would like to thank the authors of this paper for taking the time to review and answer our questions. The findings described in this paper shed a light on alternatives for the management of patients with refractory hypercholesterolemia who are not at LDL target despite treatment with a statin at a maximum tolerated dose, and a proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor.

The study described the benefits of evinacumab, a fully human monoclonal antibody against Angiopoietin-like 3, in terms of reduction of LDL cholesterol and other lipids levels in patients with refractory hypercholesterolemia. However, there is no description of the proportion of patients that reached the target LDL cholesterol at the end of the trial. As described in the discussion of your paper, previously published research has shown that with patients receiving triple therapy (a high-intensity statin, ezetimibe, and a PCSK9 inhibitor), only 45% had an LDL cholesterol level <55 mg/dL. For your study, do you have data regarding this specific outcome?